Trial Profile
A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs HuMax IL8 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 12 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 13 Feb 2023 Planned End Date changed from 8 Jun 2024 to 30 Nov 2025.
- 13 Feb 2023 Planned primary completion date changed from 28 Feb 2023 to 30 Apr 2024.